Portfolio data

OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025

• Pre-clinical companies
• OMass Therapeutics

Northern Gritstone invests in Manchester spinout Apini

Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease

• Clinical companies
• Quell Therapeutics

Beacon Therapeutics Strengthens Leadership Team with the Appointment of Dr. Daniel Chung as Chief Medical Officer

Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease

• Late-stage clinical companies
• Spur Therapeutics

Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025

• Clinical companies
• Resolution Therapeutics